RxDoctor Payments Data

Surya Rao, MD

Cardiovascular Disease · Edgewater, FLNPI 1114975596

Payments from drug & device makers

$214,155in general payments, 2019–2025

Across 534 payments — averaging $401.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$99K
  • American Regent$74K
  • Kestra Medical Technology Services, Inc.$10K
  • Impulse Dynamics (USA) Inc.$9K
  • Cvrx, Inc.$8K
  • Abbott$6K
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$7,47821%
  • Speaking & faculty fees$10,05028%
  • Travel & lodging$6,17017%
  • Food & beverage$12,66735%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,155 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$836,960
Medicare patients
1,901
Services billed
8,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban661$708,837
XareltoRivaroxaban216$230,563
EntrestoSacubitril/Valsartan191$202,067
BrilintaTicagrelor107$91,775
Repatha SureclickEvolocumab78$68,887
Dabigatran EtexilateDabigatran Etexilate Mesylate18$6,466
Valsartan175$5,392
Metoprolol Succinate379$5,188
Amiodarone Hcl131$4,929
ClopidogrelClopidogrel Bisulfate209$3,349
Atorvastatin Calcium183$2,743
Metoprolol Tartrate327$2,295
Nebivolol Hcl41$2,269
Midodrine Hcl26$2,137
Rosuvastatin Calcium118$1,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$708,837661 claims
Johnson & JohnsonXarelto$739$230,563216 claims
NovartisEntresto$99,190$202,067191 claims
AstraZenecaBrilinta$344$91,775107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Edgewater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →